Histopathological evaluation of cutaneous malignant melanoma: A retrospective study.
biomarkers
evaluation
immunohistochemistry
melanoma
prognosis
Journal
Experimental and therapeutic medicine
ISSN: 1792-1015
Titre abrégé: Exp Ther Med
Pays: Greece
ID NLM: 101531947
Informations de publication
Date de publication:
Jun 2022
Jun 2022
Historique:
received:
06
10
2021
accepted:
05
11
2022
entrez:
23
5
2022
pubmed:
24
5
2022
medline:
24
5
2022
Statut:
ppublish
Résumé
Malignant melanoma is a melanocytic neoplasm with a steadily increasing incidence worldwide. In order to define a proper diagnostic protocol and to establish an accurate prognostic method for the disease, specific biomarkers are of notable importance. Their contribution is also significant in the treatment of melanoma for the improvement of newer and more targeted therapeutic approaches. To emphasize the importance of specific immune markers in the diagnosis of melanoma, immunohistochemical analysis was performed on 56 formalin-fixed paraffin-embedded cutaneous melanomas. Besides the traditional prognostic factors, depth of invasion and mitotic rate, the markers tested in the present study were S100 protein family, Melan A, Ki67 and HMB-45. The present results indicated that immunocytochemistry represents a valuable test in the diagnosis and treatment of malignant melanoma and each biomarker had different associations with the progression and prognosis of the disease. Patients with S100 expression were 4.83 times (95% CI=1.2-20.8) more likely to suffer a relapse, whereas patients with a Ki67 expression of >30% had a 5.41-fold higher risk (95% CI=1.3-22.0). The correlation between S100 and the Breslow depth was statistically significant (r-value: 0.43; P=0.027). In addition, the importance of a multidisciplinary team including a plastic surgeon, anatomopathologist and oncologist was highlighted.
Identifiants
pubmed: 35601077
doi: 10.3892/etm.2022.11329
pii: ETM-0-0-11329
pmc: PMC9115627
doi:
Types de publication
Journal Article
Langues
eng
Pagination
402Informations de copyright
Copyright: © Gheoca Mutu et al.
Déclaration de conflit d'intérêts
The authors declare that they have no competing interests.
Références
Clin Cancer Res. 2007 Feb 1;13(3):806-15
pubmed: 17289871
Cancer. 1980 Dec 1;46(11):2492-504
pubmed: 7438021
Am J Pathol. 1982 Jun;107(3):357-61
pubmed: 6177248
Genomics. 2004 Jul;84(1):10-22
pubmed: 15203200
JAMA. 2005 Oct 5;294(13):1647-54
pubmed: 16204664
Oncol Lett. 2019 May;17(5):4102-4111
pubmed: 30944603
J Clin Oncol. 2009 Dec 20;27(36):6199-206
pubmed: 19917835
Oncol Lett. 2019 May;17(5):4188-4196
pubmed: 31007759
Biochem Biophys Res Commun. 2004 Oct 1;322(4):1111-22
pubmed: 15336958
Cytometry A. 2019 Jul;95(7):714-716
pubmed: 30512236
Mod Pathol. 1998 Aug;11(8):740-6
pubmed: 9720502
EJC Suppl. 2013 Sep;11(2):81-91
pubmed: 26217116
Arch Dermatol. 2005 Jun;141(6):745-50
pubmed: 15967921
Am J Surg Pathol. 1977 Jun;1(2):131-43
pubmed: 602975
Arch Dermatol. 2003 Dec;139(12):1620-4; discussion 1624
pubmed: 14676081
Cancer. 2006 Nov 15;107(10):2317-27
pubmed: 17039502
Hippokratia. 2008;12(4):198-204
pubmed: 19158963
Cancer Res. 2000 Apr 15;60(8):2253-7
pubmed: 10786692
Australas J Dermatol. 1991;32(1):27-37
pubmed: 1930003
Am J Surg Pathol. 1990 Aug;14(8):748-51
pubmed: 2378395
Cancer. 1994 Jul 15;74(2):782-8
pubmed: 8033061
J Dermatol Sci. 2006 Jul;43(1):1-10
pubmed: 16750612
Ann Surg. 1978 Dec;188(6):732-42
pubmed: 736651
Clin Chim Acta. 2019 Apr;491:39-45
pubmed: 30653951
Dermatol Surg. 1996 Mar;22(3):217-26
pubmed: 8599733
Cancer. 1999 Jul 15;86(2):288-99
pubmed: 10421265
Histopathology. 2000 May;36(5):387-402
pubmed: 10792480